Effects of Glycemic Variability on Regulatory T Cells in Patients with Type 2 Diabetes and Kidney Disease

References

• Valencia WM, Florez H. How to prevent the microvascular complications of type 2 diabetes beyond glucose control. BMJ. 2017;356:i6505. doi:10.1136/bmj.i6505
   PubMed Web of Science ®Google Scholar
• Wang G, Ouyang J, Li S, et al. The analysis of risk factors for diabetic nephropathy progression and the construction of a prognostic database for chronic kidney diseases. J Transl Med. 2019;17(1):264. doi:10.1186/s12967-019-2016-y
   PubMed Web of Science ®Google Scholar
• Arora MK, Singh UK. Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update. Vascul Pharmacol. 2013;58(4):259–271. doi:10.1016/j.vph.2013.01.001
   PubMed Web of Science ®Google Scholar
• Kopel J, Pena-Hernandez C, Nugent K. Evolving spectrum of diabetic nephropathy. World J Diabetes. 2019;10(5):269–279. doi:10.4239/wjd.v10.i5.269
   PubMed Web of Science ®Google Scholar
• Yoo JH, Choi MS, Ahn J, et al. Association between continuous glucose monitoring-derived time in range, other core metrics, and albuminuria in type 2 diabetes. Diabetes Technol Ther. 2020;22(10):768–776. doi:10.1089/dia.2019.0499
   PubMed Web of Science ®Google Scholar
• Wakasugi S, Mita T, Katakami N, et al. Associations between continuous glucose monitoring-derived metrics and diabetic retinopathy and albuminuria in patients with type 2 diabetes. BMJ Open Diabetes Res Care. 2021;9(1):e001923. doi:10.1136/bmjdrc-2020-001923
   PubMed Web of Science ®Google Scholar
• Nowak N. Protective factors as biomarkers and targets for prevention and treatment of diabetic nephropathy: from current human evidence to future possibilities. J Diabetes Investig. 2020;11(5):1085–1096. doi:10.1111/jdi.13257
   PubMed Web of Science ®Google Scholar
• Perez-Morales RE, Del Pino MD, Valdivielso JM, Ortiz A, Mora-Fernandez C, Navarro-Gonzalez JF. Inflammation in diabetic kidney disease. Nephron. 2019;143(1):12–16. doi:10.1159/000493278
   PubMed Web of Science ®Google Scholar
• Siegmund K, Feuerer M, Siewert C, et al. Migration matters: regulatory T-cell compartmentalization determines suppressive activity in vivo. Blood. 2005;106(9):3097–3104. doi:10.1182/blood-2005-05-1864
   PubMed Web of Science ®Google Scholar
• Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30(1):531–564. doi:10.1146/annurev.immunol.25.022106.141623
   PubMed Web of Science ®Google Scholar
• Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 2010;10(12):849–859. doi:10.1038/nri2889
   PubMed Web of Science ®Google Scholar
• Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450(7169):566–569. doi:10.1038/nature06306
   PubMed Web of Science ®Google Scholar
• Sharma R, Jarjour WN, Zheng L, Gaskin F, Fu SM, Ju ST. Large functional repertoire of regulatory T-cell suppressible autoimmune T cells in scurfy mice. J Autoimmun. 2007;29(1):10–19. doi:10.1016/j.jaut.2007.04.001
   PubMed Web of Science ®Google Scholar
• Eller K, Kirsch A, Wolf AM, et al. Potential role of regulatory T cells in reversing obesity-linked insulin resistance and diabetic nephropathy. Diabetes. 2011;60(11):2954–2962. doi:10.2337/db11-0358
   PubMed Web of Science ®Google Scholar
• Zhang C, Xiao C, Wang P, et al. The alteration of Th1/Th2/Th17/Treg paradigm in patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Hum Immunol. 2014;75(4):289–296. doi:10.1016/j.humimm.2014.02.007
   PubMed Web of Science ®Google Scholar
• Abouzeid S, Sherif N. Role of alteration in Treg/Th17 cells’ balance in nephropathic patients with type 2 diabetes mellitus. Electron Physician. 2015;7(8):1613–1618. doi:10.19082/1613
   PubMedGoogle Scholar
• Metcalf PA, Scragg RK. Comparison of WHO and ADA criteria for diagnosis of glucose status in adults. Diabetes Res Clin Pract. 2000;49(2–3):169–180. doi:10.1016/s0168-8227(00)00147-9
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612. doi:10.7326/0003-4819-150-9-200905050-00006
   PubMed Web of Science ®Google Scholar
• Hu Y, Li N, Jiang P, et al. Elevated thyroglobulin level is associated with dysfunction of regulatory T cells in patients with thyroid nodules. Endocr Connect. 2019;8(4):309–317. doi:10.1530/EC-18-0545
   PubMed Web of Science ®Google Scholar
• Monnier L, Colette C, Owens DR. Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept. Diabetes Metab Res Rev. 2009;25(5):393–402. doi:10.1002/dmrr.962
   PubMed Web of Science ®Google Scholar
• Cheng L, Yang F, Cao X, et al. The effect of short-term intensive insulin therapy on circulating T cell subpopulations in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Res Clin Pract. 2019;149:107–114. doi:10.1016/j.diabres.2019.02.007
   PubMed Web of Science ®Google Scholar
• Ceriello A, Monnier L, Owens D. Glycaemic variability in diabetes: clinical and therapeutic implications. Lancet Diabetes Endocrinol. 2019;7(3):221–230. doi:10.1016/S2213-8587(18)30136-0
   PubMed Web of Science ®Google Scholar
• Hsu CC, Chang HY, Huang MC, et al. HbA1c variability is associated with microalbuminuria development in type 2 diabetes: a 7-year prospective cohort study. Diabetologia. 2012;55(12):3163–3172. doi:10.1007/s00125-012-2700-4
   PubMed Web of Science ®Google Scholar
• Zhou JJ, Coleman R, Holman RR, Reaven P. Long-term glucose variability and risk of nephropathy complication in UKPDS, ACCORD and VADT trials. Diabetologia. 2020;63(11):2482–2485. doi:10.1007/s00125-020-05273-7
   PubMed Web of Science ®Google Scholar
• Ceriello A, De Cosmo S, Rossi MC, et al. Variability in HbA1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes. Diabetes Obes Metab. 2017;19(11):1570–1578. doi:10.1111/dom.12976
   PubMed Web of Science ®Google Scholar
• Sonoda S, Okada Y, Mori H, et al. Association between diabetic microangiopathies and glycemic variability assessed by continuous glucose monitoring. J UOEH. 2018;40(1):11–18. doi:10.7888/juoeh.40.11
   PubMedGoogle Scholar
• Watson MJ, Vignali PDA, Mullett SJ, et al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature. 2021;591(7851):645–651. doi:10.1038/s41586-020-03045-2
   PubMed Web of Science ®Google Scholar
• Khanijou V, Zafari N, Coughlan MT, MacIsaac RJ, Ekinci EI. Review of potential biomarkers of inflammation and kidney injury in diabetic kidney disease. Diabetes Metab Res Rev. 2022;38(6):e3556. doi:10.1002/dmrr.3556
   PubMed Web of Science ®Google Scholar
• Moon JY, Jeong KH, Lee TW, Ihm CG, Lim SJ, Lee SH. Aberrant recruitment and activation of T cells in diabetic nephropathy. Am J Nephrol. 2012;35(2):164–174. doi:10.1159/000334928
   PubMed Web of Science ®Google Scholar
• Lavoz C, Matus YS, Orejudo M, et al. Interleukin-17A blockade reduces albuminuria and kidney injury in an accelerated model of diabetic nephropathy. Kidney Int. 2019;95(6):1418–1432. doi:10.1016/j.kint.2018.12.031
   PubMed Web of Science ®Google Scholar
• Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH. Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients. Diabetologia. 2003;46(10):1402–1407. doi:10.1007/s00125-003-1194-5
   PubMed Web of Science ®Google Scholar
• Dalla Vestra M, Mussap M, Gallina P, et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol. 2005;16(Suppl 1):S78–S82. doi:10.1681/asn.2004110961
   PubMed Web of Science ®Google Scholar
• Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Garcia-Perez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011;7(6):327–340. doi:10.1038/nrneph.2011.51
   PubMed Web of Science ®Google Scholar
• Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, Barbosa TC, Cumano A, Bandeira A. CD25+ CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J Immunol. 2001;166(5):3008–3018. doi:10.4049/jimmunol.166.5.3008
   PubMed Web of Science ®Google Scholar
• Collison LW, Pillai MR, Chaturvedi V, Vignali DA. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J Immunol. 2009;182(10):6121–6128. doi:10.4049/jimmunol.0803646
   PubMed Web of Science ®Google Scholar
• Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med. 2005;201(7):1061–1067. doi:10.1084/jem.20042276
   PubMed Web of Science ®Google Scholar
• Tran DQ. TGF-beta: the sword, the wand, and the shield of FOXP3(+) regulatory T cells. J Mol Cell Biol. 2012;4(1):29–37. doi:10.1093/jmcb/mjr033
   PubMed Web of Science ®Google Scholar
• Cao Q, Wang Y, Zheng D, et al. IL-10/TGF-beta-modified macrophages induce regulatory T cells and protect against Adriamycin nephrosis. J Am Soc Nephrol. 2010;21(6):933–942. doi:10.1681/ASN.2009060592
   PubMed Web of Science ®Google Scholar